Risk factors for third-generation cephalosporin resistant Enterobacteriaceae in gestational urine cultures: A retrospective cohort study based on centralized electronic health records

Autoři: Alex Guri aff001;  Natalie Flaks-Manov aff003;  Adi Ghilai aff003;  Moshe Hoshen aff003;  Orna Flidel Rimon aff002;  Pnina Ciobotaro aff002;  Oren Zimhony aff002
Působiště autorů: Division of Pediatrics, Kaplan Medical Center, Rehovot, Israel aff001;  The School of Medicine, The Hebrew University and Hadassah Medical Center, Jerusalem, Israel aff002;  Clalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel aff003;  Neonatology Department, Kaplan Medical Center, Rehovot, Israel aff004;  Infectious Diseases Unit, Kaplan Medical Center, Rehovot, Israel aff005
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226515


Third-generation-cephalosporin resistant Enterobacteriaceae (3GCR-EB) carriage in pregnant women poses challenges for infection control and therapeutic decisions. The factors associated with multidrug resistant Enterobacteriaceae carriage in the gestational period are not well documented. The aim of our study was to identify risk factors associated with 3GCR-EB isolation in gestational urine cultures. The study was designed as retrospective cohort based on centralized electronic health records database. Women delivered in Clalit Health Services hospitals in Israel in 2009–2013 and provided urine culture(s) during pregnancy were included. Multivariable analysis using the Generalized Estimating Equations model was used to assess risk factors for 3GCR-EB isolation in gestational urine cultures. The study included 15,282 pregnant women with urine cultures yielding Enterobacteriaceae (EB). The proportion of 3GCR-EB in EB isolates was 3.9% (n = 603). The following risk factors were associated with 3GCR-EB isolation: multiple hospital admissions during the year before delivery (OR,1.47;95% CI,1.21–1.79), assisted fertilization procedure (OR,1.53; 95% CI,1.12–2.10), Arab ethnicity (OR,1.22; 95% CI,1.03–1.45), multiple antibiotic courses (OR,1.76; 95% CI,1.29–2.40), specifically, cephalosporins (OR,1.56; 95% CI,1.26–1.95), fluoroquinolones (OR,1.34; 95% CI,1.04–1.74), or nitrofurantoin (OR,1.29; 95% CI,1.02–1.64). The risk factors identified by this study for 3GCR-EB in gestation, can be easily generalized for pregnant women in the Israeli population. Moreover, these risk factors, other than ethnicity, are applicable to pregnant women worldwide. The information of previous antibiotic treatments, hospitalization in the last year and assisted fertilization procedure can be easily accessed and used for appropriate infection control practices and antimicrobial therapy.

Klíčová slova:

Antibiotics – Arabic people – Enterobacteriaceae – Hospitals – Medical risk factors – Pregnancy – Urine – Diabetes mellitus


1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. 2002;347(4):240–7. doi: 10.1056/NEJMoa012657 12140299.

2. Acosta CD, Kurinczuk JJ, Lucas DN, Tuffnell DJ, Sellers S, Knight M, et al. Severe maternal sepsis in the UK, 2011–2012: a national case-control study. PLoS Med. 2014;11(7):e1001672. doi: 10.1371/journal.pmed.1001672 25003759; PubMed Central PMCID: PMC4086731.

3. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2015;(8):CD000490. doi: 10.1002/14651858.CD000490.pub3 26252501.

4. Mittendorf R, Williams MA, Kass EH. Prevention of preterm delivery and low birth weight associated with asymptomatic bacteriuria. Clin Infect Dis. 1992;14(4):927–32. doi: 10.1093/clinids/14.4.927 1533541.

5. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–54. doi: 10.1086/427507 15714408.

6. Stenqvist K, Dahlen-Nilsson I, Lidin-Janson G, Lincoln K, Oden A, Rignell S, et al. Bacteriuria in pregnancy. Frequency and risk of acquisition. Am J Epidemiol. 1989;129(2):372–9. doi: 10.1093/oxfordjournals.aje.a115140 2912046.

7. Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics. 2005;115(4):942–9. doi: 10.1542/peds.2004-1289 15805368.

8. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34(5 Suppl 1):S20–8; discussion S64-73. doi: 10.1016/j.ajic.2006.05.238 16813978.

9. Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and Third-Generation-Cephalosporin Resistance among Hospitalized Patients with Urinary Tract Infections Due to Escherichia coli: Do Rates Vary by Hospital Characteristics and Geographic Region? Antimicrob Agents Chemother. 2016;60(5):3170–3. doi: 10.1128/AAC.02505-15 26926640; PubMed Central PMCID: PMC4862467.

10. Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1989;33(8):1131–6. doi: 10.1128/aac.33.8.1131 2679367; PubMed Central PMCID: PMC172613.

11. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clin Infect Dis. 2016;63(3):310–8. doi: 10.1093/cid/ciw283 27143671.

12. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56(1):52–9. doi: 10.1093/jac/dki166 15917288.

13. Villar HE, Aubert V, Baserni MN, Jugo MB. Maternal carriage of extended-spectrum beta-lactamase-producing Escherichia coli isolates in Argentina. J Chemother. 2013;25(6):324–7. doi: 10.1179/1973947813Y.0000000081 24091027.

14. Chereau F, Herindrainy P, Garin B, Huynh BT, Randrianirina F, Padget M, et al. Colonization of extended-spectrum-beta-lactamase- and NDM-1-producing Enterobacteriaceae among pregnant women in the community in a low-income country: a potential reservoir for transmission of multiresistant Enterobacteriaceae to neonates. Antimicrob Agents Chemother. 2015;59(6):3652–5. doi: 10.1128/AAC.00029-15 25845871; PubMed Central PMCID: PMC4432137.

15. Danino D, Melamed R, Sterer B, Porat N, Hazan G, Gushanski A, et al. Mother to Child Transmission of Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae. J Hosp Infect. 2018. doi: 10.1016/j.jhin.2017.12.024 29330015.

16. Jorgensen SB, Soraas A, Sundsfjord A, Liestol K, Leegaard TM, Jenum PA. Fecal carriage of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection—A three year prospective cohort study. PLoS One. 2017;12(3):e0173510. doi: 10.1371/journal.pone.0173510 28267783; PubMed Central PMCID: PMC5340397.

17. Rosen B, Waitzberg R, Merkur S. Israel: Health System Review. Health Syst Transit. 2015;17(6):1–212. 27050102.

18. CLSI. Clinical and Laboratory Standards Institute. Performance standards for antimicrobal susceptiblility testing: Eighteenth informational supplement. Document M100-S18.: Wayne, PA: Clinical and Laboratory Institute, 2008.; 2008.

19. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50(1):40–8. doi: 10.1086/649537 19995215.

20. Soraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae—a case-control study in a low prevalence country. PLoS One. 2013;8(7):e69581. doi: 10.1371/journal.pone.0069581 23936052; PubMed Central PMCID: PMC3720588.

21. Al-Assil B, Mahfoud M, Hamzeh AR. Resistance trends and risk factors of extended spectrum beta-lactamases in Escherichia coli infections in Aleppo, Syria. Am J Infect Control. 2013;41(7):597–600. doi: 10.1016/j.ajic.2012.09.016 23337303.

22. Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis. 2005;24(1):17–22. doi: 10.1007/s10096-004-1264-8 15660255.

23. Rodriguez-Bano J, Lopez-Cerero L, Navarro MD, Diaz de Alba P, Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother. 2008;62(5):1142–9. doi: 10.1093/jac/dkn293 18641033.

24. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364–75. doi: 10.1093/aje/kwf215 12578807.

25. Rettedal S, Lohr IH, Bernhoff E, Natas OB, Sundsfjord A, Oymar K. Extended-spectrum beta-lactamase-producing Enterobacteriaceae among pregnant women in Norway: prevalence and maternal-neonatal transmission. J Perinatol. 2015;35(11):907–12. doi: 10.1038/jp.2015.82 26507147.

26. Megged O. Extended-spectrum beta-lactamase-producing bacteria causing community-acquired urinary tract infections in children. Pediatr Nephrol. 2014;29(9):1583–7. doi: 10.1007/s00467-014-2810-y 24705795.

27. Ruppe E, Lixandru B, Cojocaru R, Buke C, Paramythiotou E, Angebault C, et al. Relative fecal abundance of extended-spectrum-beta-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother. 2013;57(9):4512–7. doi: 10.1128/AAC.00238-13 23836184; PubMed Central PMCID: PMC3754361.

28. Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones—a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143(2):75–8. doi: 10.1016/j.ejogrb.2008.12.007 19181435.

29. Sogaard M, Heide-Jorgensen U, Vandenbroucke JP, Schonheyder HC, Vandenbroucke-Grauls C. Risk factors for extended-spectrum beta-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study. Clin Microbiol Infect. 2017. doi: 10.1016/j.cmi.2017.03.026 28377310.

30. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161–82, Table of Contents. doi: 10.1128/CMR.00036-08 19136439; PubMed Central PMCID: PMC2620637.

Článek vyšel v časopise


2020 Číslo 1